# Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling-enforcement-policy/4320b2a8-6f77-4cbf-8a20-7b9631fcf4fe

> FDA guidance document: Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy. Issue date: June 03, 2003. Get complete insights and analysis.

---

## Details

- Title: Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2003-06-03
- Last Changed: 2020-04-28
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2003-D-0090">FDA-2003-D-0090</a>

## Related Documents

- [Nonclinical Safety Evaluation of Pediatric Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-evaluation-of-pediatric-drug-products/a5729b5c-7a6e-40c1-861d-e8acf3cd178a)
- [Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications](https://www.globalkeysolutions.net/guidances/guidance-document/levothyroxine-sodium-products-enforcement-of-august-14-2001-compliance-date-and-submission-of-new-applications/2d5e2030-11b1-4414-8987-9ca957a899b5)
- [Integration of Dose-Counting Mechanisms into MDI Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/integration-of-dose-counting-mechanisms-into-mdi-drug-products/b523d7a1-3c0a-423e-ac27-f899492e96ff)